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ARTICLE
Non-coding RNAs participate in the regulatory
network of CLDN4 via ceRNA mediated miRNA
evasion
Yong-xi Song1, Jing-xu Sun1, Jun-hua Zhao1, Yu-chong Yang1, Jin-xin Shi1, Zhong-hua Wu1, Xiao-wan Chen1,
Peng Gao1, Zhi-feng Miao1,2 & Zhen-ning Wang1
Thousands of genes have been well demonstrated to play important roles in cancer
progression. As genes do not function in isolation, they can be grouped into “networks” based
on their interactions. In this study, we discover a network regulating Claudin-4 in gastric
cancer. We observe that Claudin-4 is up-regulated in gastric cancer and is associated with
poor prognosis. Claudin-4 reinforce proliferation, invasion, and EMT in AGS, HGC-27,
and SGC-7901 cells, which could be reversed by miR-596 and miR-3620-3p. In addition,
lncRNA-KRTAP5-AS1 and lncRNA-TUBB2A could act as competing endogenous RNAs to
affect the function of Claudin-4. Our results suggest that non-coding RNAs play important
roles in the regulatory network of Claudin-4. As such, non-coding RNAs should be considered
as potential biomarkers and therapeutic targets against gastric cancer.
DOI: 10.1038/s41467-017-00304-1 OPEN
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Gastric cancer (GC) is one of the most common cancers,with a heavy mortality rate all over the world1. Metastasis,an end consequence of numerous complex processes,
presents a major challenge in clinical practice and accounts for a
major source of mortality and recurrence in GC2. During the
complex process of metastasis, primary cancer cells undergo a
sequential series of events including local dissemination, intra-
vasation into the vascular system, survival in the circulatory
system, extravasation out of the vascular system, and regrowth at
distant sites3–5. Up to now, many molecular mechanisms of
metastasis have been investigated, but the role of potential net-
works between mRNA and non-coding RNAs (ncRNAs) has not
been fully elucidated.
Recently, studies have started to characterize the regulatory
effects that ncRNAs may have on GC6–8. These ncRNAs are
closely associated with the occurrence, development, invasion,
and metastasis of tumors, as well as drug resistance9–13. Among
these ncRNAs, microRNAs (miRNAs) and long non-coding
RNAs (lncRNAs) have appealed to a large group of researchers
and become a main focus of attention. Increasing evidence
has uncovered the indispensable function of miRNAs in post-
transcriptional regulation of oncogenes and tumor suppressor
genes, thus modulating the biological behaviors of tumor cells
such as invasion, metastasis, proliferation, and apoptosis14, 15.
LncRNAs are now known to have many functions, acting as
scaffolds or guides to regulate interactions between protein and
genes, as decoys to bind proteins or miRNAs, and as enhancers to
modulate transcription of their targets after being transcribed
from enhancer regions or their neighboring loci16–22. Moreover,
increasing studies have indicated that some discrepantly
expressed lncRNAs possess signiﬁcant regulatory effects on
carcinogenesis and the development of cancer, demonstrating
their potential roles in both oncogenic and tumor-suppressive
pathways23–27. Intriguingly, some recent studies report a brand-
new lncRNAs regulatory circuitry in which lncRNAs may function
as competing endogenous RNAs (ceRNAs) and crosstalk with
mRNAs by competitively binding their common miRNAs23, 28–30.
In the present study, six pairs of gastric cancer tissues and non-
tumorous adjacent tissues were analyzed using microarray,
and abnormally expressed mRNAs, miRNAs, and lncRNAs were
selected for deep analysis. Following bioinformatic analyses, the
network of claudin-4 (CLDN4), which is involved in metastasis of
GC, captured our attention. The claudin family is well known for
its pivotal role in the constitution and maintenance of tight
junctions31. CLDN4, a critical member of the claudin family, has
been observed to alter expression patterns in various types of
carcinomas including gastric cancer32, pancreatic cancer33, and
ovarian cancer34. In addition, we have previously demonstrated
aberrant expression of CLDN4 in GC and precursor lesions35.
Using meta-analysis, we have also found that CLDN4 expression
is associated with increasing pT category, tumor size, and lymph
node metastasis in patients with GC36. Simultaneously, accu-
mulating evidence conﬁrms that aberrant expression of CLDN4
may result in an intense tendency towards metastasis of cancers,
mainly because CLDN4 can enhance the invasion capacity
of cancer cells and promote epithelial-mesenchymal transition
(EMT)37, 38. Overexpression of CLDN4 is positively associated
with the expression of metalloproteinase-2 (MMP-2) and
metalloproteinase-9 (MMP-9), both of which exhibit the ability to
degrade components of the extracellular matrix and eventually
reinforce the invasive capacity and motility of cancer cells38–40.
Particularly, due to the critical role of CLDN4 in the formation of
tight junctions, disruption and dysfunction of tight junctions
originating from the aberrant expression of CLDN4 may decrease
the stability of cell-to-cell adhesions and thus facilitate the
detachment and metastasis of cancer cells.
Although there have been several studies focusing on investi-
gating the expression proﬁle and function of CLDN4 in different
cancers, the upstream regulatory mechanism of CLDN4 has
rarely been explored until now. Neither miRNAs nor lncRNAs
have been reported to participate in the direct regulation of
CLDN4. In our current work, we have discovered the existence of
several miRNAs and lncRNAs which may cause abnormal
expression of CLDN4. Furthermore, on the basis of microarray
and experimental analyses, we propose a regulatory network in
which CLDN4 is regulated by these ncRNAs in a ceRNA-
mediated miRNA evasion, thus contributing to the metastasis and
progression of GC.
Results
CLDN4 is identiﬁed as a target of miR-596 and miR-3620-3p.
In an attempt to identify the regulatory networks of mRNA
and ncRNAs in GC, six pairs of GC tissues and non-tumorous
adjacent tissues were analyzed via microarray using the Human
LncRNA+mRNA Array v3.0 together with the miRCURY
LNATM microRNA Array. These six patients consisted of four
males and two females, with an average age of 66.84 years.
Detailed characteristics and values for each individual patient are
shown in Supplementary Table 1 and Supplementary Data 1–3.
In total, 235 miRNAs were found to be differentially expressed
between GC and non-tumorous adjacent tissues (Supplementary
Data 4), including 173 that were up-regulated and 62 that were
down-regulated more than two fold. In total 4329 lncRNAs were
found to be signiﬁcantly differentially expressed (Supplementary
Data 5), of which 1974 were up-regulated and 2355 down-
regulated. In total 3369 differentially expressed mRNAs were also
identiﬁed, with 1816 up-regulated and 1553 down-regulated more
than two fold (Supplementary Data 6). Hierarchical clustering
was applied to show expression patterns of miRNA, lncRNA, and
mRNA (Fig. 1a). These mRNA microarray results were then
intersected with predicted target genes of the differentially
expressed miRNAs (Supplementary Data 7). Moreover, GO
analysis (Supplementary Fig. 1a, b) and pathway analysis
(Supplementary Fig. 1c, Supplementary Data 8) were also applied
to analyze the differentially expressed mRNAs. GO analysis
indicated the most signiﬁcant Biological Processes, Cellular
Components, and Molecular Function. Pathway analysis
indicated that the most signiﬁcant pathways consisted of
Staphylcoccus aureus infection, cell cycle, chemical carcinogenesis,
and so on. According to the pathway analysis results, we selected
four classical pathways related to cancer development: “Cell
adhesion”, “Pathway in cancer”, “Tight junction”, and “Cell
cycle”. Combined with the lncRNA and miRNA microarray
results, an mRNA-ceRNA analysis was performed on choosing
classical genes within these four pathways (Fig. 1b). Details
regarding the process of pathway analysis, mRNA-ceRNA ana-
lysis, and selection of key genes are listed in Supplementary
Methods.
In the mRNA-ceRNA analysis results for the “Tight junction”
pathway, CLDN4, which is closely related to cancer
development41, 42, drew our attention. Validations were
performed to verify the relationship between CLDN4 and its
correlative miRNAs. Initially, TargetScan (Release 7.1) results
showed that CLDN4 contained predicted miR-596, miR-3620-3p,
and miR-4292 targeting sites (Fig. 1c). We veriﬁed that
CLDN4 expression could be negatively regulated by miR-596,
miR-3620-3p, and miR-4292 at both the transcriptional (Fig. 1d)
and translational (Fig. 1e) levels, as measured by real-time
PCR and western blotting, respectively. To test the effects
of these miRNAs on gene expression, we transfected the
luciferase reporter plasmid psiCHECK2-CLDN4 into GC cells.
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Overexpression of miR-596 and miR-3620-3p, but not miR-4292,
miR-596-mut, miR-3620-3p-mut, miR-4292-mut, or miRNA
negative control (miR-NC), decreased the luciferase activity of
psiCHECK2-CLDN4 (Fig. 1f). In summary, according to
microarray results and bioinformatic analysis, we selected four
pathway networks and identiﬁed CLDN4 as a target of interest.
Through real-time PCR, western blotting, and luciferase assays,
we veriﬁed the network related to CLDN4 and proved that
CLDN4 is a target gene of miR-596 and miR-3620-3p.
The biological function of CLDN4 in vitro. To test the biological
function of CLDN4 and further verify its association with miR-
596 and miR-3620-3p, we stably overexpressed CLDN4 in SGC-
7901, AGS, and HGC-27 cells (Supplementary Fig. 2a). This
CLDN4 up-regulation caused by stable transfection could be
overcome at both the transcriptional and translational levels by
ectopic overexpression of miR-596 or miR-3620-3p (Fig. 1g). By
performing Cell Counting Kit-8 (CCK-8) assays, we found that
CLDN4 overexpression could signiﬁcantly increase the pro-
liferative capacity of SGC-7901, AGS, and HGC-27 cells com-
pared with parallel stable cell lines containing empty vector pEX-
2 (pEX2-NC cells). This increase could be eliminated when miR-
596 or miR-3620-3p, but not miR-596-mut or miR-3620-3p-mut,
were transfected. To examine the effect of CLDN4 on cell inva-














































































































































































































Position 59-65 of CLDN4 3′ UTR
Position 254-260 of CLDN4 3′ UTR









Fig. 1 CLDN4 is identiﬁed as a target of miR-596 and miR-3620-3p. a Hierarchical clustering analysis of mRNAs, lncRNAs, and miRNAs that were
differentially expressed between GC tissues and non-tumorous adjacent tissues (>2.0-fold; P< 0.05; ﬁltered to show the top 30 up-regulated or
down-regulated results for mRNAs and lncRNAs). Expression values are represented in shades of red and green, indicating expression above and below the
median expression value across all tissues, respectively. b The mRNA-lncRNA -miRNA networks in the GC. The networks include cell adhesion pathway,
pathway in cancer, tight junction pathway, and cell cycle pathway. Genes colored in green are protein-coding RNAs associated with GC. Genes colored in
blue are lncRNAs and genes colored in red are miRNAs associated with GC. c Predicted binding sites for miR-596, miR-3620-3p, and miR-4292 on the
CLDN4 transcript. The white nucleotides are the seed sequences of miRNAs. d Real-time PCR analysis of CLDN4 expression in GC cells treated with
mimics of miR-596, miR-3620-3p, miR-4292, and negative control. e GC cell line SGC-7901 was transfected with the mimics of miR-596, miR-3620-3p,
miR-4292, and negative control. Reduced CLDN4 expression was shown by western blotting analysis and normalized to β-tubulin. f Luciferase activities
were measured in GC cells co-transfected with luciferase reporter containing CLDN4 and the mimics of miR-596, miR-3620-3p, miR-4292, or mutant.
Data are presented as the relative ratio of renilla luciferase activity and ﬁreﬂy luciferase activity. g The relative expressions of CLDN4 were determined
by real-time PCR and western blotting. Data are shown as mean± s.d., n= 3. The data statistical signiﬁcance is assessed by Student’s t-test. *P< 0.05,
**P< 0.01
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motility assays in vitro. These experiments showed that CLDN4
overexpression could signiﬁcantly increase the invasion ability of
GC cells, compared with pEX2-NC cells, and this increase could
again be partially abolished when miR-596 or miR-3620-3p were
transfected (Fig. 2a–f, Supplementary Fig. 2b, c). To further
support these results, we stably knocked down endogenous
CLDN4 in SGC-7901, AGS, and HGC-27 cells using lentiviral
shRNA (LV3-sh-CLDN4 cells) (Supplementary Fig. 2d). The
CCK-8 assays showed that the proliferation of LV3-sh-CLDN4
cells was signiﬁcantly slower than parallel stable cell lines
transfected with scrambled shRNA (LV3-sh-NC cells). LV3-sh-
CLDN4 cells also showed attenuated invasion ability compared
with LV3-sh-NC cells. The reduction in proliferative capacity
and invasion ability caused by knocking down CLDN4 could be
largely rescued by inhibition of miR-596 or miR-3620-3p
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Fig. 2 CLDN4 reinforces the proliferative and invasive capacity of GC cells in vitro. a Cell proliferation was assessed daily for 4 days using the Cell Counting
Kit-8 (CCK-8) assay in CLDN4 overexpressing SGC-7901 cells. b Transwell assays were used to evaluate the involvement of CLDN4 for invasion in CLDN4
overexpressing SGC-7901 cells. c Scrape motility assays were monitored at 0, 6, 12, and 24 h in CLDN4 overexpressing SGC-7901 cells. d Cell proliferation
assessed in CLDN4 overexpressing AGS cells. e Transwell assays assessed in CLDN4 overexpressing AGS cells. f Scrape motility assays in CLDN4
overexpressing AGS cells. g Cell proliferation assessed in CLDN4 knockdown SGC-7901 cells. h Transwell assays assessed in CLDN4 knockdown
SGC-7901 cells. i Scrape motility assays in CLDN4 knockdown SGC-7901 cells. j Cell proliferation assessed in CLDN4 knockdown AGS cells. k Transwell
assays assessed in CLDN4 knockdown AGS cells. l Scrape motility assays in CLDN4 knockdown AGS cells. In b, e, h, and k, cells were incubated for 24 h,
and counted under the microscope. Original magniﬁcation ×200. Scale bars= 100 μm. Data are shown as mean± s.d., n= 3. The data statistical
signiﬁcance is assessed by Student’s t-test. *P< 0.05, **P< 0.01
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Fig. 3 CLDN4 induces EMT in vitro. a Phase-contrast micrographs of CLDN4 overexpressing cells, pEX2-NC cells and SGC-7901 cells. Scale bars= 50 μm.
b, c The transcriptional and translational levels of EMT related markers. The real-time PCR and western blotting were performed at 48 h after the CLDN4
overexpressing cells treated with mimics of miR-596 or miR-3620-3p. d Immunoﬂuorescence microscopy of the localization and expression of EMT and
invasion markers in CLDN4 overexpressing cells. Scale bars= 50 μm. e The relative expression levels of CLDN4 in human GC tissues compared with their
matched non-tumorous adjacent tissues. f Kaplan–Meier analysis of the correlation between CLDN4 expression levels and overall survival. g, h The relative
expression levels of miR-596 and miR-3620-3p in human GC tissues compared with their matched non-tumorous adjacent tissues. i, j The correlation
between CLDN4 transcriptional levels and miR-596 or miR-3620-3p transcriptional levels were measured in the same set of patients by Spearman
correlation analysis. k Representative images of CLDN4, miR-596 and miR-3620-3p expression from GC tissues and non-tumorous adjacent tissues by
ISH assays. Original magniﬁcation × 200. Scale bars= 100μm. Data are shown as mean± s.d., n= 3. The data statistical signiﬁcance is assessed by
Student’s t-test and Wilcoxon’s Sign Rank Test is used to evaluate the differential expression between GC tissues and their matched non-tumorous
adjacent tissues. *P< 0.05, **P< 0.01
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Having found that CLDN4 could regulate cell proliferation, we
analyzed differences in cell-cycle distribution and apoptosis
following CLDN4 overexpression to further investigate its
mechanism. We noted that CLDN4 had no obvious inﬂuence
on cell-cycle distribution (Supplementary Fig. 3a) or apoptosis
(Supplementary Fig. 3b). To our surprise, miR-596 or miR-3620-
3p could promote apoptosis (Supplementary Fig. 3b), suggesting
that other target genes of the miRNAs may contribute to this
interesting result. Afterwards, to evaluate whether the effects of
these two miRNAs on cell proliferation and invasion were mainly
dependent on CLDN4, we transfected the two miRNAs into
CLDN4 knockdown cells. The two miRNAs had little effect on
cell proliferation and metastasis when CLDN4 was knocked down
(Supplementary Fig. 3c, d).
While performing the above experiments, we noticed that
CLDN4 overexpression induced mesenchymal-like morphologi-
cal features in GC cells (Fig. 3a). We subsequently studied the
correlations between CLDN4 and EMT-related genes at both the
transcriptional and translational levels to further investigate
the mechanism of how CLDN4 may regulate cell invasion
(Supplementary Fig. 4a, b). We analyzed epithelial markers
(E-cadherin, syndecan 1, mucin-1, Cytokeratin, desmoplakin,
laminin, and ZO-1), mesenchymal markers (N-cadherin,
β-catenin, ﬁbronectin 1, α-SMA, Twist1, FOXC2, FSP-1, SNAI1,
slug, vimentin, ZEB-1, and ZEB-2), and invasion related markers
(MMP2, MMP9) via real-time PCR and western blotting. We saw
that overexpression of CLDN4, compared with pEX2-NC cells,
could reduce E-cadherin and Cytokeratin expression and enhance
expression of N-cadherin, β-catenin, Twist1, ZEB-2, and MMP9.
As expected, miR-596 and miR-3620-3p could partially abolish
these effects (Fig. 3b, c). Validations performed in AGS and
HGC-27 cells showed similar results to those in SGC-7901 cells
supporting that CLDN4 could promote EMT across cell lines
(Supplementary Fig. 4c, d). Immunoﬂuorescence staining was
used to further conﬁrm these observations. We found that
CLDN4 induced loss of E-cadherin and Cytokeratin expression
and increased N-cadherin and MMP-9, all of which were partially
abolished by miR-596 and miR-3620-3p transfection (Fig. 3d).
In summary, through functional experiments, real-time PCR,
western blotting, and immunoﬂuorescence staining, we revealed
functions of CLDN4 in promoting cell proliferation, invasion,
and EMT. Simultaneously, we revealed that miR-596 and
miR-3620-3p could partially abolish these functions.
The expression of CLDN4 and miRNAs in GC tissues. To
further investigate the role of CLDN4 in human GC, we per-
formed deep validations in 104 pairs of GC tissues and non-
tumorous adjacent tissues. With 76.92% of patients showing
higher expression in cancer tissue, the transcriptional level of
CLDN4 was signiﬁcantly higher in the GC tissues compared with
matched non-tumorous adjacent tissues via Wilcoxon’s Sign
Rank Test (P< 0.001, Fig. 3e, Supplementary Fig. 4e). Subse-
quently, we examined whether CLDN4 expression was related to
the prognosis of GC after gastrectomy. Using the Kaplan–Meier
analysis with log-rank test for these 104 patients, we found that
higher CLDN4 expression level was signiﬁcantly correlated with
decreased overall survival (P= 0.001, Fig. 3f). Furthermore, the
result of Cox multivariate analysis revealed that higher CLDN4
expression was an independent predictor for poor prognosis in
GC (HR= 2.634, 95% CI= 1.536–4.517, P< 0.001, Supplemen-
tary Table 2). As CLDN4 has been proven to be a target gene of
miR-596 and miR-3620-3p, we also examined the expression of
these miRNAs in the same tissues. The expression levels of miR-
596 and miR-3620-3p were both signiﬁcantly lower in the GC
tissues (P< 0.001 for both, Supplementary Fig. 4e). In addition
70.19% and 66.35% of patients showed lower miR-596 expression
and miR-3620-3p expression in GC tissues compared with mat-
ched non-tumorous adjacent tissues, respectively (Fig. 3g, h). Not
surprisingly, the signiﬁcant negative correlations between CLDN4
expression and miR-596, miR-3620-3p expression were con-
ﬁrmed by the Spearman correlation coefﬁcients (P< 0.001 for
both, Fig. 3i, j, Supplementary Fig. 5). These data support that
high CLDN4 expression in GC tissues is associated with poorer
survival and negatively associated with expression of miR-596
and miR-3620-3p. In situ hybridization (ISH) results in 20 cases
of GC showed that CLDN4, miR-596, and miR-3620-3p were
expressed by epithelial and carcinoma cells and mainly localized
in the cytoplasm. Furthermore, the expression patterns detected
by ISH were consistent with the real-time PCR results (Fig. 3k).
LncRNAs can crosstalk with miRNAs through direct binding.
To identify lncRNAs which may interact with miR-596 or miR-
3620-3p and serve as ceRNAs, we performed experiments
focusing on the previously mentioned “Tight junction” network
(Fig. 1b). Among 14 candidate lncRNAs, lncRNA-KRTAP5-AS1
presented the most obvious down-regulation in response to
overexpression of miR-596. Simultaneously, expression of
lncRNA-TUBB2A and lncRNA-KRTAP5-AS1 decreased the
most following miR-3620-3p overexpression (Fig. 4a). To test the
speciﬁcity of these regulatory interactions, we performed RNA-
sequencing on six gastric cancer cell lines (SGC-7901 cells over-
expressing miR-596, overexpressing miR-3620-3p, miRNA
negative control, overexpressing lncRNA-KRTAP5-AS1, over-
expressing lncRNA-TUBB2A, or lncRNA negative control). In
cells overexpressing miR-596, the expression of CLDN4 (fold-
change of FPKM= 0.125) and lncRNA-KRTAP5-AS1 (fold-
change of FPKM= 0.760) were down-regulated. In addition, the
expression of CLDN4 (fold-change of FPKM= 0.543), lncRNA-
TUBB2A (fold-change of FPKM= 0.854), and lncRNA-KRTAP5-
AS1 (fold-change of FPKM= 0.280) were all down-regulated in
cells overexpressing miR-3620-3p compared with the control
group. Interestingly, increased CLDN4 expression was found in
cells overexpressing lncRNA-KRTAP5-AS1 (fold-change of
FPKM= 14.168) or lncRNA-TUBB2A (fold-change of FPKM=
12.051) (Supplementary Data 9).
LncRNA-KRTAP5-AS1, located on chromosome 11 and with a
length of 2554 nucleotides, has ﬁve predicted miR-3620-3p
targeting sites and ﬁve predicted miR-596 targeting sites.
LncRNA-TUBB2A, located on chromosome 6 and with a length
of 1052 nucleotides, has ﬁve predicted miR-3620-3p targeting
sites (Supplementary Figs. 6, 7). We found that lncRNA-
KRTAP5-AS1 and lncRNA-TUBB2A presented the same
cytoplasmic localization as CLDN4 and the miRNAs through
ISH. We then transfected the luciferase reporter plasmids
psiCHECK2-lncRNA-TUBB2A and psiCHECK2-lncRNA-
KRTAP5-AS1 into GC cells to test for potential effects that the
miRNAs may have on the expression of the lncRNAs. Over-
expression of miR-596 and miR-3620-3p, but not miR-596-mut,
miR-3620-3p-mut, or miR-NC, decreased the luciferase activity
of psiCHECK2-KRTAP5-AS1 (Fig. 4b). The luciferase activity of
psiCHECK2-TUBB2A could be decreased by miR-3620-3p, but
not miR-3620-3p-mut or miR-NC (Fig. 4c). Afterwards, we
performed RNA immunoprecipitation (RIP) experiments to
further investigate the potential direct binding between
lncRNA-KRTAP5-AS1, lncRNA-TUBB2A, and the miRNAs. To
construct plasmids that could produce lncRNAs identiﬁed by the
MS2 protein, we subcloned an MS2-12X fragment into
pcDNA3.1, pcDNA3.1- KRTAP5-AS1, pcDNA3.1-TUBB2A,
pcDNA3.1-KRTAP5-AS1-mut, and pcDNA3.1-TUBB2A-mut
plasmids. We also constructed a GFP and MS2 gene fusion
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expression vector to produce a GFP-MS2 fusion protein which
could speciﬁcally bind the MS2-12X fragment and be identiﬁed
using an anti-GFP antibody. Thus, miRNAs which interact with
lncRNA-KRTAP5-AS1 or lncRNA-TUBB2A could be pulled
down by the GFP-MS2-lncRNA compounds and analyzed via
real-time PCR. We observed that the lncRNA-KRTAP5-AS1 RIP
in SGC-7901 and AGS cells was signiﬁcantly enriched for both
miR-596 and miR-3620-3p compared to pcDNA3.1-KRTAP5-
AS1-mut or empty vector (MS2) (Fig. 4d). Likewise, lncRNA-
TUBB2A, but not lncRNA-TUBB2A-mut RIP, was enriched for
miR-3620-3p. Subsequent RNA pull-down experiments provided
more solid evidence for these speciﬁc associations between the
miRNAs and lncRNAs. LncRNA-TUBB2A, lncRNA-KRTAP5-
AS1, lncRNA-TUBB2A-mut, and lncRNA-KRTAP5-AS1-mut
were transcribed in vitro from pGEM-T-lncRNA-TUBB2A,
pGEM-T-lncRNA-KRTAP5-AS1, pGEM-T-lncRNA-TUBB2A-mut
and pGEM-T-lncRNA-KRTAP5-mut vectors, respectively. The
in vitro transcription products were then labeled with biotin,
incubated with cell lysates before isolation with streptavidin
agarose beads and analyzed via real-time PCR. MiR-3620-3p
could be pulled down by biotin-labeled lncRNA-TUBB2A and
lncRNA-KRTAP5-AS1, but not lncRNA-TUBB2A-mut or
lncRNA-KRTAP5-AS1-mut. At the same time, biotin-labeled
lncRNA-KRTAP5-AS1, but not lncRNA-KRTAP5-AS1-mut,
could also bind miR-596 (Fig. 4e). These data reveal that
lncRNA-KRTAP5-AS1 can bind miR-596 and miR-3620-3p. At
the same time, lncRNA-TUBB2A can bind miR-3620-3p.
LncRNAs act as ceRNAs to regulate cell function in vitro. In
order to test the biological functions of these two lncRNAs, we
performed gain- and loss-of-function studies in GC cancer cells.
We stably overexpressed or knocked down lncRNA-KRTAP5-
AS1 in SGC-7901, AGS, and HGC-27 cells (Supplementary
Fig. 8a, b). LncRNA-KRTAP5-AS1 overexpression led to
increased proliferative capacity, as measured by the CCK-8 assay.
When we explored its effect using transwell assays, lncRNA-
KRTAP5-AS1 strongly promoted cell invasion ability. Not
surprisingly, miR-596 and miR-3620-3p could abolish both bio-
logical functions caused by lncRNA-KRTAP5-AS1 (Fig. 5a–d,
Supplementary Fig. 8c, d). In contrast, knockdown of endogenous
lncRNA-KRTAP5-AS1 expression dramatically reduced the pro-
liferative capacity and invasion ability of AGS cells. As expected,
inhibition of miR-596 or miR-3620-3p could again decrease these














































































































































































































































































































































































































































Fig. 4 LncRNAs can crosstalk with miRNAs through direct binding. a Relative expression of lncRNAs in GC cells treated with mimics of miR-596 or
miR-3620-3p were measured by real-time PCR. b Luciferase activity in GC cells co-transfected with luciferase reporter containing lncRNA-KRTAP5-AS1
and the mimics of miR-596, miR-3620-3p or mutant. Data are presented as the relative ratio of renilla luciferase activity and ﬁreﬂy luciferase activity.
c Luciferase activity in GC cells co-transfected with luciferase reporter containing lncRNA-TUBB2A and the mimics of miR-3620-3p or mutant.
Data are presented as the relative ratio of renilla luciferase activity and ﬁreﬂy luciferase activity. d The schematic diagram and real-time PCR results of
the MS2-RIP method used to identify the binding between lncRNAs and miRNAs in both SGC-7901 and AGS cells. e The schematic diagram of the RNA pull
down method used to identify the binding between lncRNAs and miRNAs in both SGC-7901 and AGS cells. GC cell lysates were incubated with biotin-
labeled lncRNA-KRTAP5-AS1, lncRNA-TUBB2A, lncRNA-KRTAP5-AS1-mut, and lncRNA-TUBB2A-mut. MiRNA real-time PCR was performed after pull
down process. Data are shown as mean± s.d., n= 3. The data statistical signiﬁcance is assessed by Student’s t-test. *P< 0.05, **P< 0.01
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Similar experiments were performed to test the biological
functions of lncRNA-TUBB2A by stable overexpression and
suppression in SGC-7901, AGS, and HGC-27 cells (Supplemen-
tary Fig. 8g, h). Brieﬂy, by CCK-8 and transwell experiments,
lncRNA-TUBB2A overexpression was found to increase the
proliferative capacity and invasion ability of GC cells, an effect
which could be partially eliminated by miR-3620-3p (Fig. 5i–l,
Supplementary Fig. 8i, j). In contrast, inhibition of miR-3620-3p
could rescue the reduction in proliferative capacity and invasion
ability caused by lncRNA-TUBB2A knockdown (Fig. 5m–p,
Supplementary Fig. 8k, l).
To identify whether lncRNA-KRTAP5-AS1 and lncRNA-
TUBB2A act as ceRNAs in the CLDN4 regulatory network, we
transfected the luciferase reporter plasmid psiCHECK-CLDN4
into GC cells. LncRNA-KRATP5-AS1 could increase its luciferase
activity, and this was abolished by miR-596 and miR-3620-3p.
Similarly, miR-3620-3p could partially eliminate the effect of
lncRNA-TUBB2A on increasing the luciferase activity of
psiCHECK2-CLDN4 (Fig. 6a). Moreover, we performed RIP
assays based on Ago2, which can enrich for targets bound
by miRNAs upon immunoprecipitation. We separately over-
expressed lncRNA-KRTAP5-AS1 and lncRNA-TUBB2A in
SGC-7901 and AGS cells then pulled down Ago2 using an
anti-Ago2 antibody. Overexpression of lncRNA-KRTAP5-AS1 or
lncRNA-TUBB2A both caused a signiﬁcant decrease in the
enrichment of CLDN4 transcripts pulled down by Ago2 (Fig. 6b),
indicating that there were less miRNA-bound CLDN4 transcripts









































































































































































































































































































































































































































































































































































































Fig. 5 LncRNA-KRTAP5-AS1 and lncRNA-TUBB2A enhance the proliferative and invasive capacity of GC cells in vitro. a Cell proliferation was assessed
daily for 4 days using the CCK-8 assay in lncRNA-KRTAP5-AS1 overexpressing SGC-7901 cells. b Transwell assays were used to evaluate the involvement
of lncRNA-KRTAP5-AS1 for invasion in lncRNA-KRTAP5-AS1 overexpressing SGC-7901 cells. c Cell proliferation assessed in lncRNA-KRTAP5-AS1
overexpressing AGS cells. d Transwell assays assessed in lncRNA-KRTAP5-AS1 overexpressing AGS cells. e Cell proliferation assessed in lncRNA-
KRTAP5-AS1 knockdown SGC-7901 cells. f Transwell assays assessed in lncRNA-KRTAP5-AS1 knockdown SGC-7901 cells. g Cell proliferation assessed in
lncRNA-KRTAP5-AS1 knockdown AGS cells. h Transwell assays assessed in lncRNA-KRTAP5-AS1 knockdown AGS cells. i Cell proliferation assessed in
lncRNA-TUBB2A overexpressing SGC-7901 cells. j Transwell assays assessed in lncRNA-TUBB2A overexpressing SGC-7901 cells. k Cell proliferation
assessed in lncRNA-TUBB2A overexpressing AGS cells. l Transwell assays assessed in lncRNA-TUBB2A overexpressing AGS cells. m Cell proliferation
assessed in lncRNA-TUBB2A knockdown SGC-7901 cells. n Transwell assays assessed in lncRNA-TUBB2A knockdown SGC-7901 cells. o Cell proliferation
assessed in lncRNA-TUBB2A knockdown AGS cells. p Transwell assays assessed in lncRNA-TUBB2A knockdown AGS cells. In b, d, f, h, j, l, n, p, cells were
incubated for 24 h, and counted under the microscope. Original magniﬁcation × 200. Scale bars= 100 μm. Data are shown as mean± s.d., n= 3. The data
statistical signiﬁcance is assessed by Student’s t-test. *P< 0.05, **P< 0.01
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lncRNA-TUBB2A can compete with the CLDN4 transcript for
the binding of miRNAs. To shed more light on this aspect, we
overexpressed these two lncRNAs into CLDN4 overexpressing
cells. The expression of CLDN4, which could be down regulated
by miR-596 and miR-3620-3p as we demonstrated above, could
be enhanced at both the transcriptional and translational level by
lncRNA-KRTAP5-AS1 or lncRNA-TUBB2A (Fig. 6c). The ability
of CLDN4 to promote cell proliferation and invasion in vitro
could be abolished by miR-596 and miR-3620-3p, as mentioned
above, and overexpression of lncRNA-KRTAP5-AS1 or lncRNA-
TUBB2A in CLDN4 cells signiﬁcantly further increased these
abilities (Fig. 6d, e). Subsequently, the EMT-inducing effects of
these two lncRNAs were measured. The downregulation of
epithelial markers (E-cadherin, Cytokeratin) and the upregulation
of mesenchymal markers and invasion related markers
(N-cadherin, ZEB-2, MMP9) induced by CLDN4 were exagger-
ated after either lncRNA was overexpressed. These results
were veriﬁed at both the transcriptional and translational levels
(Fig. 6f, g). In summary, we found that through functioning as
ceRNAs to regulate CLDN4 expression, lncRNA-KRTAP5-AS1
and lncRNA-TUBB2A can promote cell proliferation, invasion,
and EMT. LncRNA-KRTAP5-AS1 appears to serve as a ceRNA
for miR-596 and miR-3620-3p while lncRNA-TUBB2A serves as


























































































































































































































































































































































































































































































































































Fig. 6 LncRNA-KRTAP5-AS1 and LncRNA-TUBB2A act as ceRNAs. a Luciferase activity in GC cells co-transfected with psiCHECK2-CLDN4 and ceRNAs.
Data were presented as the relative ratio of renilla luciferase activity and ﬁreﬂy luciferase activity. b The schematic diagram and real-time PCR results of the
RIP based on Ago2 showed that lncRNAs can compete with the CLDN4 transcript for the binding of miRNAs. c The relative expression levels of CLDN4
were determined by real-time PCR and western blotting after co-transfecting ceRNAs. d Cell proliferation was assessed daily for 4 days using the CCK-8
assay in CLDN4 overexpressed cells transfected the plasmids of pcDNA3.1-KRTAP5-AS1 and pcDNA3.1 -TUBB2A. e Transwell assays were used to assay
the involvement of CLDN4 for invasion in CLDN4 overexpressing cells. Cells were incubated for 24 h, and counted under the microscope. Original
magniﬁcation ×200. Scale bars= 100 μm. f, g The transcriptional and translational levels of EMT related markers. The real-time PCR and western
blotting were performed at 48 h after the CLDN4 overexpressing cells treated with pcDNA3.1-KRTAP5-AS1 and pcDNA3.1-TUBB2A. Data are shown
as mean± s.d., n= 3. The data statistical signiﬁcance is assessed by Student’s t-test. *P< 0.05, **P< 0.01
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Non-coding RNAs regulate the function of CLDN4 in vivo. To
evaluate the biological functions of these genes in vivo, different
SGC-7901 or HGC-27 cells were subcutaneously or intravenously
injected into nude mice. In total, there were six groups: Group 1
(pEX2-NC) was injected with pEX2-NC cells; Group 2 (CLDN4)
was injected with CLDN4 overexpressing cells; Group 3 (miR-596
+CLDN4) was injected with CLDN4 overexpressing cells trans-
fected with miR-596 mimics; Group 4 (miR-3620-3p+CLDN4)
was injected with CLDN4 overexpressing cells transfected with
miR-3620-3p mimics; Group 5 (lncRNA-KRTAP5-AS1+CLDN4)
was injected with CLDN4 overexpressing cells transfected
with lncRNA-KRTAP5-AS1; and Group 6 (lncRNA-TUBB2A
+CLDN4) was injected with CLDN4 overexpressing cells trans-
fected with lncRNA-TUBB2A. We found that tumor lumps in the
CLDN4 group were signiﬁcantly larger than in the pEX2-NC
group, and that miR-596 and miR-3620-3p could partially
reduce the growth trend caused by CLDN4. Moreover, the
tumor volumes in the lncRNA overexpressing groups were larger
than in the CLDN4 overexpressing group. At the end of the
experiment, the mice were sacriﬁced and we measured the
volume and weight of the tumor lumps in each group (Fig. 7a, b).
For SGC-7901 cells, the mean tumor volume at the time of death
in mice injected with CLDN4 overexpressing cells was 1.34± 0.39
(mean value± s.d.) cm3 and the mean tumor volume of mice
injected with NC cells was 0.47± 0.12 cm3. The mean tumor
volumes in the miR-596+CLDN4 and miR-3620-3p+CLDN4
groups were both smaller (0.87± 0.31 cm3 and 0.75± 0.38 cm3,
respectively) than in the CLDN4 overexpressing group.
Moreover, the tumor volumes in the lncRNA-KRTAP5-AS1

































































































Fig. 7 CLDN4 promotes proliferation in vivo. a In vivo tumor lumps of xenograft mouse models composed of CLDN4 overexpressing cells, which were
treated with miR-596 or miR-3620-3p as well as pcDNA3.1-KRTAP5-AS1 or pcDNA3.1-TUBB2A. Mice were sacriﬁced at the 19th day after injection
and each tumor lump was removed from the body. b Images of the tumor lumps of each group at the endpoint of the experiment described in a. c The
tumor growth curves of in vivo tumor volumes. Data are mean± s.d. of the tumor volumes, n= 8, *P< 0.05. d The mean tumor weight of each group.
Data are shown as mean± s.d. of the tumor weights, n= 8. The data statistical signiﬁcance is assessed by Student’s t-test. *P< 0.05, **P< 0.01
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Fig. 8 The effects of CLDN4 and ncRNAs on tumor growth. SGC-7901 cells were subcutaneously injected at both right and left armpit regions of nude
mice. After tumor formation, plasmids of CLDN4, lncRNAs and agomirs of miRNAs were injected into tumors of right side and their negative controls into
left side. a Treatment of CLDN4 promoted xenograft tumor growth. b, c Treatment of miR-596 and miR-3620-3p suppressed xenograft tumor growth.
d, e Treatment of pcDNA3.1-KRTAP5-AS1 and pcDNA3.1-TUBB2A promoted xenograft tumor growth. f, g miR-596 and miR-3620-3p treated tumors
showed less CLDN4 expression. hmiR-596 and miR-3620-3p treated tumors showed less IncRNA-KRTAP5-AS1 expression. imiR-3620-3p treated tumors
showed less IncRNA-TUBB2A expression. Data are shown as mean± s.d., n= 5 for each group. The data statistical signiﬁcance is assessed by Student’s
t-test. *P< 0.05, **P< 0.01
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(1.58± 0.21 cm3 and 1.49± 0.21 cm3, respectively) than in the
CLDN4 group, which supported the ﬁndings of the in vitro
experiments (Fig. 7c). Xenograft tumors grown from CLDN4 cells
had greater mean weights than those grown from pEX2-NC cells
(0.84± 0.13 g vs. 0.25± 0.05 g) (Fig. 7d). Also, the tumor
weights were lower in the miR-596 group (0.54± 0.20 g) and
miR-3620-3p group (0.51± 0.20 g) than in the CLDN4 over-
expressing group, but much higher in the lncRNA-KRTAP5-AS1
+CLDN4 and lncRNA-TUBB2A+CLDN4 groups (1.04± 0.11 g
and 1.03± 0.13 g, respectively). The experiments using HGC-27
cells showed similar effects as the SGC-7901 cells (Supplementary
Fig. 9). Thus, consistent with our in vitro ﬁndings, we further
found that the effect of CLDN4 on increasing tumor proliferation
could be rescued by miR-596 or miR-3620-3p and enlarged when
lncRNA-KRTAP5-AS1 or lncRNA-TUBB2A were overexpressed
in the nude mouse model. To test whether these effects were
consistent once tumors had already formed, we subcutaneously
injected the same amount of SGC-7901 cells into both sides of
nude mice. Once the tumors had formed, we injected plasmids of
CLDN4, the lncRNAs, or agomirs of the miRNAs into the tumors
on one side and their negative controls into that on the other side.
The injections were performed ﬁve times at an interval of 2 days
between each injection (i.e., day 9, 12, 15…). 3 days after the last
injection, the mice were sacriﬁced and the volumes and weights of
their tumors were measured. The results showed that CLDN4,
lncRNA-TUBB2A, and lncRNA-KRTAP5-AS1 could promote
proliferation even after tumor formation compared with their
negative controls and that tumor proliferation could be sup-
pressed by miR-596 and miR-3620-3p (Fig. 8a–e). Furthermore,





















































































































































































































Fig. 9 The metastasis promoting effect of CLDN4 could be regulated in vivo. a, b Transverse section of 18F-FDG PET images of mice at the 56 day
after tail vein injection with 1 × 106 SGC-7901 cell clones and the max SUVs were analyzed in each group. Data are mean± s.d. of the tumor volumes, n= 8,
*P< 0.05. c The gross lesion of lung tissues isolated from the mice. d The microscopic images of lung tissue sections stained by hematoxylin and eosin.
Scale bars= 500μm. e The number of metastatic nodules in the lungs from 56 days after tail vein injection in a (ﬁve sections evaluated per lung). Data are
mean± s.d. of the tumor volumes, n= 8, *P< 0.05. f, g Transverse section of 18F-FDG PET images of mice at the 56 day after tail vein injection with 1 × 106
HGC-27 cell clones and the max SUVs were analyzed in each group. Data are shown as mean± s.d. of the tumor volumes, n= 8. The data statistical
signiﬁcance is assessed by Student’s t-test. *P< 0.05
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expression on the transcriptional and translational levels and less
lncRNA -KRTAP5-AS1 on the transcriptional level. Similarly,
tumors injected with miR-3620-3p agomir showed less CLDN4,
lncRNA-TUBB2A, and lncRNA -KRTAP5-AS1 expression
(Fig. 8f–i).
To examine the inﬂuence these genes had on metastasis in vivo,
the same six groups of cell clones were intravenously injected into
nude mice via the tail vein. After 8 weeks of the injection,
Positron Emission Tomography (PET) scanning was performed
on each mouse. The results of the PET scans revealed that
SGC-7901 cells overexpressing CLDN4 caused greater lung
tumor formation, with a higher maximum standardized uptake
value (SUVmax) of 1.94± 0.55 compared to pEX2-NC cells
(1.04± 0.40). At the same time, the SUVmax in the miR-596
+CLDN4 and miR-3620-3p+CLDN4 groups were signiﬁcantly
smaller (1.31± 0.53 and 1.14± 0.58, respectively) than those in
the CLDN4 group. The SUVmax were 3.18± 1.24 in the lncRNA-
KRTAP5-AS1+CLDN4 group and 3.38± 0.73 in the lncRNA-
TUBB2A+CLDN4 group, both of which were larger than the
CLDN4 group (Fig. 9a, b). Following PET scanning, mice were
sacriﬁced and the morphological characteristics of their lungs
were examined to support the PET scan results (Fig. 9c). We
observed that the metastatic lesions at the surface of the lungs
were more plentiful in the CLDN4 group than in the NC group,
but more scarce and harder to observe in the miR-596 and
miR-3620-3p+CLDN4 groups. Importantly, we also found that
there were more metastatic lesions in the lncRNA+CLDN4
groups compared with the CLDN4 group. Afterwards,
hematoxylin-eosin staining was performed on each lung and
the numbers of metastatic nodules were counted under the
microscope. Consistent with the PET scan results and morpho-
logical characteristics, there were signiﬁcantly more metastatic
nodules in the lungs of mice injected with CLDN4 overexpressing
cells compared with pEX2-NC cells (9.89± 5.53 vs. 2.14± 0.56).
The average number of metastatic nodules was 4.11± 1.64 in the
miR-596+CLDN4 group and 4.57± 1.38 in the miR-3620-3p
+CLDN4 group, showing a rescue of the tumor-promoting effects
caused by CLDN4 overexpression. For lncRNA-KRTAP5-AS1
+CLDN4 and lncRNA-TUBB2A+CLDN4 groups, the numbers
of metastatic nodules were 15.43± 4.15 and 16.66± 6.45,
respectively, with both increased compared to the CLDN4 group
(Fig. 9d, e). Veriﬁcation experiments performed in HGC-27 cells
further supported the above observations (Fig. 9f, g). In summary,
we used subcutaneously transplanted tumor models and tumor
metastasis models to test the effects of different cell clones on
proliferation and metastasis in vivo. Through PET scanning,
morphological observation, and hematoxylin-eosin staining,
we revealed that CLDN4 promotes proliferation and metastasis
in vivo, which could be inhibited by miR-596 and miR-3620-3p
and enhanced by lncRNA-KRTAP5-AS1 and lncRNA-TUBB2A.
Discussion
With the development of molecular biology techniques, many
molecular mechanisms of GC are now being revealed43, 44.
Thousands of genes have already been demonstrated to play
important roles in many cancer processes. It is known that genes
generally do not function alone, so they can be grouped into
“networks” based on their interactions. In this study, we used
microarrays and RNA-sequencing to identify the regulatory
networks of mRNAs and ncRNAs in GC. Among the results of
the analysis for potential mRNA–ceRNA interactions in the
“Tight junction” pathway, CLDN4 goaded our interest since it is
closely related to cancer development.
Although there is still some controversy regarding the role














Fig. 10 The mechanism graph of the regulatory network and function of CLDN4. CLDN4 could promote proliferation, metastasis or EMT processes of GC,
which could be inhibited by miR-596, miR-3620-3p and enhanced by lncRNA-KRTAP5-AS1, lncRNA-TUBB2A as ceRNAs
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oncogenic functions for CLDN4 such as enhancing proliferation,
invasion, and EMT37, 38. Moreover, we have previously demon-
strated aberrant expression of CLDN4 in GC and precursor
lesions35. In our current work, we validated the oncogenic
function of CLDN4 in reinforcing the proliferative, invasive, and
metastatic capacities of GC cells and promoting EMT through a
series of functional experiments both in vitro and in vivo. The
oncogenic role of CLDN4 in enhancing invasion and EMT is
supported by previous studies showing that claudin family
members can activate MMP and ZEB family members38, 45. In
addition, the proliferation and metastasis promoting effects of
CLDN4 in vivo can be partially explained by its ability to promote
vasculogenic mimicry formation46. Up to now, studies have
shown that epigenetic alterations may directly lead to the aberrant
expression of CLDN447, 48, but the regulatory mechanisms of
CLDN4 still remained to be elucidated in GC, especially regarding
the role of ncRNAs in CLDN4 regulation. Given the signiﬁcant
effects of CLDN4 on cancer metastasis, as revealed by our work
and others, the regulatory network related to CLDN4 urgently
needed to be explored. In this study, we found that CLDN4,
a common target of miR-596 and miR-3620-3p, can signiﬁcantly
enhance the proliferation and invasion of GC cells both in vitro
and in vivo. These effects of CLDN4 are decreased upon
exogenous introduction of miR-596 and miR-3620-3p. We also
observed that CLDN4, whose expression is negatively associated
with the expression of miR-596 and miR-3620-3p, is up-regulated
in GC tissues and signiﬁcantly correlates with poor survival for
GC patients. In contrast with the inhibitory role of the above
miRNAs on CLDN4, our results show that exogenous introduc-
tion of lncRNA-KRTAP5-AS1 and lncRNA-TUBB2A can elevate
the effects of CLDN4 on proliferation and invasion. All of
these results drove us to propose the existence of a noteworthy
regulatory network in which miRNAs and lncRNAs interact with
each other to co-regulate the expression pattern and function of
CLDN4 (Fig. 10).
In recent years, the functions of ncRNAs have drawn more and
more attention49. The functions and regulatory mechanisms of
miRNAs are continuously becoming more deeply understood.
Nevertheless, we present that the expression and function of
CLDN4 can be negatively regulated by two miRNAs, miR-596,
and miR-3620-3p, both of which were largely enigmatic before
this study. Unlike miRNAs, the functions of lncRNAs remain
largely unknown. Accumulating evidence has indicated that
lncRNAs can function as ceRNAs for miRNAs in cancer50. For
example, Yuan et al. showed that lncRNA-ATB functions as a
ceRNA for miR-200s, thereby regulating the expression of ZEB1
and ZEB2 in hepatic cellular carcinoma51. Liu et al52. showed that
lncRNA-HOTAIR can regulate HER2 expression by acting as a
sponge for miR-331-3p in GC. Likewise, LncRNA-ARSR can act
as a ceRNA for miR-34 and miR-449 to facilitate AXL and
c-MET expression, thus promoting sunitinib resistance in renal
cell carcinoma53. Here, we show that lncRNA-KRTAP5-AS1 acts
as an oncogene in vitro through binding miR-596 and miR-3620-
3p and lncRNA-TUBB2A functions similarly through binding
miR-3620-3p. This indicates that these two lncRNAs can
serve as ceRNAs. Subsequent investigations such as luciferase
activity assays, RIP based on Ago2 and in vivo experiments
further conﬁrmed that these two lncRNAs function as ceRNAs to
regulate CLDN4.
As shown above, ncRNAs may regulate multiple targets in
different cells using different binding regions. Moreover, one gene
can be regulated by multiple ncRNAs. Thus, ncRNAs and
mRNAs can build complicated networks. Although we demon-
strate that the effects of CLDN4 on invasion and proliferation are
fully due to its direct interaction with miR-596 and miR-3620-3p,
our results indicate that these two miRNAs may also be involved
in other regulatory circuits. During examination of cell apoptosis,
we found that miR-596 and miR-3620-3p could signiﬁcantly
promote GC cell apoptosis, whereas there was no obvious dif-
ference in apoptosis between CLDN4 overexpressing cells and
pEX2-NC cells. This regulatory function of miR-596 on cell
apoptosis is in accordance with the results of a previous study54.
As it is well known that a single miRNA can bind multiple target
mRNAs through miRNA response elements (MREs)23, 55, 56, it is
rational that miR-596 and miR-3620-3p could regulate cell
apoptosis through targeting additional transcripts in addition to
the CLDN4 regulatory network. Likewise, although the lncRNA-
KRTAP5-AS1 and lncRNA-TUBB2A can interact with miR-596
and miR-3620-3p to regulate EMT, we observed some differences
among the EMT markers. These multiplex results are supported
by studies showing that lncRNAs, which possess the capacity to
function as ceRNAs, can target MREs for various mRNA-
targeting miRNAs, similar to how miRNAs can target multiple
mRNAs55, 56. These ﬁndings imply that the lncRNAs may also
participate in some additional regulatory networks. Therefore,
further studies are warranted to deeply investigate these
additional regulatory networks.
In summary, we reported a regulatory network for CLDN4 in
GC. We observed that CLDN4 was up-regulated in GC and
associated with poor prognosis. CLDN4 reinforced proliferation,
invasion, and EMT in GC cells, which could be reversed by
miR-596 and miR-3620-3p. In addition, lncRNA-KRTAP5-AS1
and lncRNA-TUBB2A could act as ceRNA to increase these
functions of CLDN4. These results reveal that ncRNAs play
important roles in the regulatory network of CLDN4. As such,
ncRNAs should be considered as potential biomarkers and
therapeutic targets against GC.
Methods
Tissues. One hundred and four GC tissues and matched non-tumorous adjacent
tissues were obtained from patients who were newly diagnosed and received
surgical resection at the First Afﬁliated Hospital of China Medical University,
between 2007 and 2011 (detailed information seen in Supplementary Data 10).
Informed consent was obtained from all patients enrolled in this study. Histological
grade was staged according to the seventh TNM staging of the International Union
against Cancer (UICC)/American Joint Committee on Cancer (AJCC) system. All
research complied with the principles of the Declaration of Helsinki, and approval
was acquired from the Research Ethics Committee of the First Afﬁliated Hospital of
China Medical University.
Cell culture. SGC-7901, HGC-27 (purchased from the Institute of Biochemistry
and Cell Biology at the Chinese Academy of Sciences, Shanghai, China), and AGS
cells (obtained from ATCC, Manassas, VA) were cultured at 37 °C in RPMI 1640
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum in a humidiﬁed incubator in an atmosphere containing 5% CO2 (Thermo,
Waltham, MA, USA). None of cell lines used in this paper were listed in the
database of commonly misidentiﬁed cell lines maintained by ICLAC. All cell lines
were free of mycoplasma contamination.
Microarray analysis. Six match-paired sets of tissues for microarray were obtained
from patients who were newly diagnosed with GC and received radical resection at
the First Afﬁliated Hospital of China Medical University. Total RNA was extracted
from the above tissues. The Quick Amp Labeling kit (Agilent Technologies, Palo
Alto CA, USA) was used to amplify and transcribe the RNA into cRNA, then the
labeled cRNA was hybridized onto the Human LncRNA Array v3.0 (8 × 60 K,
ArrayStar, Rockville, MD, USA) using the Agilent Gene Expression Hybridization
Kit (Agilent Technologies). Total miRNAs were labeled using the miRCURYTM
(Hy3TM/Hy5TM) power labeling kit (Exiqon Life Sciences, Vedbaek, Denmark)
and hybridized onto the miRCURY LNA microRNA array (v18.0) (Exiqon Life
Sciences). The arrays were scanned with an Axon GenePix 4000B microarray
scanner following the washing step. The acquired array images were extracted and
analyzed using Agilent Feature Extraction Software v10.7. Raw signal intensities
were normalized in a quantile method by GeneSpring GX v11.5.1 (Agilent
Technologies), and low intensity lncRNAs, mRNAs, and miRNAs were ﬁltered.
LncRNAs, mRNAs, and miRNAs that were signiﬁcantly differentially expressed
were identiﬁed using box plot and scatter plot ﬁltering. The threshold used to
screen upregulated or downregulated lncRNAs, mRNAs and miRNAs was fold
change> 2.0 with a P-value < 0.05.
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RNA isolation and real-time PCR. Total RNA was extracted using Trizol reagent
(Invitrogen). Poly-A tails were added to the miRNA according to the protocol of
the Poly (A) Tailing Kit (Ambion, Waltham, MA, USA). The PrimeScriptTM RT
reagent Kit with gDNA Eraser (Takara, Dalian, China), and gene-speciﬁc primers
or random primers were used to generate cDNA. Real-time PCR was performed
in a Light Cycler 480 II Real-Time PCR system (Roche Diagnostics, Basel,
Switzerland) using SYBR® Green (Takara). Glyceraldehyde phosphate
dehydrogenase (GAPDH) and U6 snRNA were employed as endogenous controls
for mRNA/lncRNA and miRNA, respectively. The comparative Ct method was
used to calculate the relative expression of RNAs. Primer sequences are displayed
in Supplementary Data 11.
Luciferase reporter assay. Luciferase reporters were generated based on the
psiCHECK2 vector (Promega). To construct psiCHECK2-CLDN4, the complete 3′
UTR of human CLDN4 mRNA (853nt, UCSC accession no. uc003tzh.2),
containing the putative miR-596 and miR-3620-3p binding sites, was ampliﬁed and
cloned into the psiCHECK2 vector. For the lncRNAs, full-length sequences of
lncRNA-TUBB2A (1052nt, UCSC accession no. uc011dhu.1) and lncRNA-
KRTAP5-AS1 (2554nt, UCSC accession no. uc001ltt.1) were PCR ampliﬁed and
cloned into the psiCHECK2 vector. The luciferase reporter was co-transfected with
miR-596 mimics, miR-3620-3p mimics, miR-4292 mimics, miR-596-mut mimics,
miR-3620-3p-mut mimics, or miR-NC into SGC-7901 cells by Lipofectamine 2000
according to the manufacturer’s guidelines. The relative luciferase activity was
measured with the Dual-Luciferase Reporter Assay System (Promega) and Inﬁnate
M200 PRO microplate reader (Tecan, Shanghai, China).
Western blotting analysis. Total cell lysates were obtained using the Total Protein
Extraction Kit (KeyGen Biotech). Proteins were separated by SDS-polyacrylamide
gel electrophoresis (SDS–PAGE) and transferred to PVDF membranes (Millipore).
Membranes were immunoblotted with primary antibodies (Supplementary
Table 3). After incubation with peroxidase-conjugated afﬁnipure goat anti-mouse
IgG or peroxidase-conjugated afﬁnipure goat anti-rabbit IgG, the blots were
detected using the GelCapture version software (DNR Bio-Imaging Systems,
Jerusalem, Israel).The loading control for the western blotting was β-tubulin. Main
uncropped immunoblots are provided in Supplementary Fig. 10.
Transfection. Transfections were performed using the Lipofectamine 2000
Reagent (Invitrogen) following the manufacturer’s protocol. Final concentrations
of 50 nM of miRNA mimics and 0.75 µg/ml plasmids were used for each trans-
fection in a six well plate with 2 ml culture medium. For lentivirus transfection,
cells were transfected with 5 × 106 transducing units of lentivirus. The stable cell
lines were constructed using G418 (200 μg ml−1) or puromycin (200 μg ml−1).
Sequences for shRNAs and RNA oligoribonucleotides are listed in Supplementary
Tables 4, 5.
Cell Counting Kit-8 proliferation assay. The capacity for cellular proliferation
was measured using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories,
Kumamoto, Japan) according to the manufacturer’s instructions. The optical
density was determined with a microplate reader (Bio-Rad, Hercules, CA, USA) at
a wavelength of 450 nm.
Transwell invasion assay. The transwell invasion assay was conducted using the
transwell (Corning, NY, USA) and matrigel (BD Biosciences, San Jose, CA, USA)
according to the manufacturer’s instructions. Cells (~5 × 104) were added into the
upper compartment of the chamber. After 24 h of incubation at 37°C with 5% CO2,
the number of cells invading through the matrigel was counted in 10 randomly
selected visual ﬁelds from the central and peripheral portions of the ﬁlter using a
Leica DM3000 microscope (Leica, Wetzlar, Germany).
Scrape motility assay. Scrape motility assays were performed by scratching the
cell monolayer with a sterile 200 µl pipette tip, and the scratched areas were
photographed at × 100 magniﬁcation using Leica DMI3000B computer-assisted
microscope (Leica). Images were captured at 0, 6, 12, and 24 h after the scratch was
made. Images were analyzed using Image-Pro Plus v6.0 image analysis software
(Media Cybernetics, Rockville, MD, USA).
Fluorescence-activated cell sorting. Cells were trypsinized and resuspended to
generate single-cell suspensions. For cell-cycle analysis, detached cells were ﬁxed
overnight in 70% ethanol at 4 °C, stained with propidium iodide in a cell cycle
detection kit (KeyGen Biotech, Nanjing, China) according to the manufacturer’s
instructions, and analyzed using a FACS calibur ﬂow cytometer (BD Biosciences)
and BD Cell Quest software. To study apoptosis, cells were stained with Annexin
V-APC and propidium iodide (Annexin V-APC Apotosis Detection Kit, KeyGEN)
according to the manufacturer’s instructions. Samples were analyzed using the
LSRFortessa (BD Bioscience).
Immunoﬂuorescence analysis. Different cells were cultured and ﬁxed in a 48-well
culture board and incubated with antibodies speciﬁc for E-cadherin (1:200, Abcam,
ab76055), Cytokeratin (1:250, Abcam, ab53280), N-cadherin (1:200, Abcam,
ab76011), or MMP-9(1:200, Abcam, ab119906). After incubating with goat anti-
rabbit IgG (1:1000, Alexa Fluor594, Invitrogen, A-21207) and goat anti-mouse IgG
(1:1000, Alexa Fluor594, Invitrogen, A-11032), the nuclei were stained by adding
DAPI (1:1000, Invitrogen, D3571). Finally the cells were observed via Leica
DMI3000 B (Leica).
RNA-sequencing. Six groups of SGC-7901 cells (purchased from the Institute of
Biochemistry and Cell Biology at the Chinese Academy of Sciences, Shanghai,
China) were cultured and then separately transfected with miR-596 mimics,
miR-3620-3p mimics, miR-NC, pcDNA3.1-KRTAP5-AS1, pcDNA3.1-TUBB2A,
or pcDNA3.1 before being prepared for massive RNA sequencing. Total RNA from
the cell lines was extracted using Trizol reagent (Invitrogen), and gene-speciﬁc
primers or random primers were used to generate cDNA. After quantitative
analysis and quality inspection, we constructed sequencing libraries using the
KAPA Stranded RNA-Seq Library Prep Kit (Illumina). RNA-sequencing was
performed on an Illumina HiSeq 4000 Sequencing System with 150 cycles. After
the data preprocessing, gene level fragments per kilobase of exon per million
fragments mapped (FPKM)57 were calculated. Details regarding the process of the
RNA-sequencing and data analysis were listed in the Supplementary Methods.
RNA pull-down. LncRNA-TUBB2A and lncRNA-KRTAP5-AS1 were transcribed
in vitro from pGEM-T-lncRNA-TUBB2A or pGEM-T-lncRNA-KRTAP5-AS1
vectors, respectively. Simultaneously, LncRNA-TUBB2A-mut and lncRNA-
KRTAP5-AS1-mut were transcribed from pGEM-T-lncRNA-TUBB2A-mut or
pGEM-T-lncRNA-KRTAP5 -AS1-mut vectors with their corresponding miRNA
binding sites mutated. Altogether with transcripts transcribed from pGEM-T (used
as the negative control), all ﬁve transcripts were biotin-labeled with the Biotin RNA
Labeling Mix (Roche, Basel, Switzerland) and T7 RNA polymerase (Roche), treated
with RNase-free DNase I (Roche), and puriﬁed with an RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). One milligram of whole-cell lysates from SGC-7901 cells or
AGS cells was incubated with three micrograms of puriﬁed biotinylated transcripts
for 1 h at 25 °C. The complexes were isolated by streptavidin agarose beads
(Invitrogen). Any RNA present in the pull-down material was detected by real-time
PCR analysis.
RNA immunoprecipitation. SGC-7901 and AGS cells were co-transfected with
pcDNA3.1-MS2, pcDNA3.1-MS2- TUBB2A, pcDNA3.1-MS2-KRTAP5-AS1,
pcDNA3.1-MS2-TUBB2A-mut, pcDNA 3.1-MS2-KRTAP5-AS1-mut, or pMS2-
GFP (Addgene). After 48 h, the transfected cells were used in RNA immunopre-
cipitation (RIP) experiments using the Magna RIPTM RNA-Binding Protein
Immunoprecipitation Kit (Millipore, Bedford, MA, USA) and an anti-GFP anti-
body (Roche) according to the manufacturer’s instructions. The RNA fraction
isolated by RIP was quantiﬁed using a Nano-Photometer spectrophotometer in the
UV and visible spectra (Implen, Munich, Germany). Real-time PCR was used to
evaluate the expression levels of miRNAs.
RIP based on Ago2. SGC-7901 and AGS cells were transfected with pcDNA3.1-
KRTAP5-AS1, pcDNA3.1-TUBB2A, or pcDNA3.1. After 48 h, cells were used to
perform RIP experiments using an anti-Ago2 antibody (Millipore, Bedford, MA,
USA) and the Magna RIPTM RNA-Binding Protein Immunoprecipitation Kit
(Millipore, Bedford, MA, USA), according to the manufacturer’s instructions.
RNAs were isolated from the immunoprecipitation products and quantiﬁed by a
Nano-Photometer spectrophotometer in the UV and visible spectra (Implen,
Munich, Germany). Real-time PCR was performed to examine the expression
levels of lncRNAs and CLDN4.
In situ hybridization. In situ hybridization (ISH) was performed by applying
the ISH Kit (Boster, Bio-Engineering Company, Wuhan, China). Formalin-ﬁxed
parafﬁn embedded (FFPE) tissue slides were deparafﬁnized and deproteinated.
Slides were then prehybridized in prehybridization solution for 2 h at 42 °C and
incubated in DIG-labeled probe solution over night at 42 °C. After stringent
washing, the slides were then exposed to a streptavidin-peroxidase reaction system
and stained with 3, 3′diaminobenzidine (DAB, ZSGB-BIO, Beijing, China).
Hematoxylin was used to counterstain the slides.
Animal experiments. 2 × 106 SGC-7901 or HGC-27 cells in 0.2 ml PBS were
subcutaneously injected into the right armpit region of 48 ﬁve-week-old female
BALB/c nude mice which were randomly divided into six groups (n= 8 for each
group). The tumor size was measured every 2 days with calipers. Nineteen days
after injection, the mice were sacriﬁced and the subcutaneous tumors were isolated
and measured.
For experiments in existing tumors, 2 × 106 SGC-7901 cells in 0.2 ml PBS were
subcutaneously injected at both right and left armpits regions of 25 nude mice
which were randomly divided into ﬁve groups (n= 5 for each group). After tumors
formed, 10 µg plasmid of CLDN4 and lncRNAs or 1.5 nmol miRNA agomir of
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miRNAs were injected into the tumors on the right side with their negative
controls injected into the left side. The injections were performed ﬁve times at an
interval of 2 days between each injection (i.e., day 9, 12, 15…). Tumor formation in
each mouse was monitored every 3 days before the injection of plasmid or agomir
by taking two-dimensional measurements of the tumor. After 3 days of the last
injection, the mice were sacriﬁced and the volume and weight of their tumors were
measured. The tumor volume was calculated with the formula: (L ×W2)/2, where
L is the length and W is the width of the tumor.
For metastasis experiments, 1 × 106 SGC-7901 or HGC-27 cells in 0.1 ml PBS
were injected into the tail vein of 48 ﬁve-week-old female BALB/c nude mice which
were randomly divided into six groups (n= 8 for each group). After 8 weeks of
injection, 18-ﬂuorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
scans were performed using a PET scanner (Metis 1800, Madic Technology Co,
Ltd). Before 18F-FDG administration, the mice were fasted for at least four hours.
Each mouse was injected intravenously with 7–12 MBq of 18F-FDG via the tail
vein. The 18F-FDG was metabolized for 30 min after injection and then PET
scanning was performed for 30 min. Afterwards, the PET images were carefully
evaluated by two experienced nuclear medicine physicians. For semi-quantitative
analysis, the maximum standardized uptake value (SUVmax) was measured and
calculated according to the following formula:
SUV= The radioactive concentration in the tumor lesion (MBq/g) × Body
weight of mice (g)/The injected dose of 18F-FDG (MBq).
After the 18F-FDG PET scan, intact lung tissues were isolated from the mice
and tissue sections were stained with hematoxylin and eosin. The numbers of
metastatic cancer nests were counted at 10 × 10 magniﬁcations using an inverted
microscope (Leica DMI300B).
For all animal experiments, the operators and investigators were blinded to the
group allocation. All experimental procedures involving animals were done in
accordance with the Guide for the Care and Use of Laboratory Animals (NIH
publication no. 80-23, revised 1996) and the institutional ethical guidelines for
animal experiments.
Statistical analysis. All statistical analyses in this study were performed using
SPSS 20.0 software (IBM Corp, Armonk, NY, USA). Data are listed as mean
value± s.d. Student’s t-test was used when the variance between groups are similar,
and the Wilcoxon signed rank test was used when the variance between groups are
not similar The Kaplan–Meier method with log-rank test, Spearman’s correlation
analysis, and Cox multivariate analysis were used as mentioned above. The tumor
marker prognostic analysis was performed following the REMARK reporting
guidelines58. A P-value <0.05 from a two-tailed test was considered signiﬁcant.
Data availability. The microarray data are deposited in the NCBI Gene Expression
Omnibus (GEO) datasets under the accession number GSE99417. The RNA
sequence data generated in this study are deposited in the NCBI Sequence Read
Archive (SRA) database under the SRA number SRP106526. The authors declare
that all the data supporting the ﬁndings in this study are available in this study and
its Supplementary Information, or are available from the corresponding author
through reasonable request.
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